Literature DB >> 25989449

The dengue vaccine pipeline: Implications for the future of dengue control.

Lauren M Schwartz1, M Elizabeth Halloran2, Anna P Durbin3, Ira M Longini4.   

Abstract

Dengue has become the most rapidly expanding mosquito-borne infectious disease on the planet, surpassing malaria and infecting at least 390 million people per year. There is no effective treatment for dengue illness other than supportive care, especially for severe cases. Symptoms can be mild or life-threatening as in dengue hemorrhagic fever and dengue shock syndrome. Vector control has been only partially successful in decreasing dengue transmission. The potential use of safe and effective tetravalent dengue vaccines is an attractive addition to prevent disease or minimize the possibility of epidemics. There are currently no licensed dengue vaccines. This review summarizes the current status of all dengue vaccine candidates in clinical evaluation. Currently five candidate vaccines are in human clinical trials. One has completed two Phase III trials, two are in Phase II trials, and three are in Phase I testing.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clinical trial; Dengue vaccine; Dengue virus; Efficacy; Vaccine

Mesh：

Substances：

Year:  2015        PMID： 25989449      PMCID： PMC4470297          DOI： 10.1016/j.vaccine.2015.05.010

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  40 in total

Review 1.  Dengue vector-control services: how do they work? A systematic literature review and country case studies.

Authors:  Olaf Horstick; Silvia Runge-Ranzinger; Michael B Nathan; Axel Kroeger
Journal:  Trans R Soc Trop Med Hyg       Date:  2010-04-18       Impact factor: 2.184

2.  Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.

Authors:  Charmagne G Beckett; Jeffrey Tjaden; Timothy Burgess; Janine R Danko; Cindy Tamminga; Monika Simmons; Shuenn-Jue Wu; Peifang Sun; Tadeusz Kochel; Kanakatte Raviprakash; Curtis G Hayes; Kevin R Porter
Journal:  Vaccine       Date:  2010-11-25       Impact factor: 3.641

Review 3.  Dengue: a continuing global threat.

Authors:  Maria G Guzman; Scott B Halstead; Harvey Artsob; Philippe Buchy; Jeremy Farrar; Duane J Gubler; Elizabeth Hunsperger; Axel Kroeger; Harold S Margolis; Eric Martínez; Michael B Nathan; Jose Luis Pelegrino; Cameron Simmons; Sutee Yoksan; Rosanna W Peeling
Journal:  Nat Rev Microbiol       Date:  2010-12       Impact factor: 60.633

4.  Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

Authors:  Anna P Durbin; Alexander Schmidt; Dan Elwood; Kimberli A Wanionek; Janece Lovchik; Bhavin Thumar; Brian R Murphy; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2010-12-14       Impact factor: 5.226

5.  The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations.

Authors:  T Walker; P H Johnson; L A Moreira; I Iturbe-Ormaetxe; F D Frentiu; C J McMeniman; Y S Leong; Y Dong; J Axford; P Kriesner; A L Lloyd; S A Ritchie; S L O'Neill; A A Hoffmann
Journal:  Nature       Date:  2011-08-24       Impact factor: 49.962

Review 6.  From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Bruno Guy; Beatrice Barrere; Claire Malinowski; Melanie Saville; Remy Teyssou; Jean Lang
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

7.  Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.

Authors:  Beth D Kirkpatrick; Anna P Durbin; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Sean A Diehl; Dan Elwood; Adrienne P Jarvis; Beulah P Sabundayo; Caroline E Lyon; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Steven S Whitehead
Journal:  J Infect Dis       Date:  2015-03-22       Impact factor: 5.226

Review 8.  Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

Authors:  Jorge E Osorio; Claire Y-H Huang; Richard M Kinney; Dan T Stinchcomb
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

Review 9.  The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Authors:  Beth-Ann G Coller; David E Clements; Andrew J Bett; Sangeetha L Sagar; Jan H Ter Meulen
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

10.  Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.

Authors:  Rosario Z Capeding; Imelda A Luna; Emily Bomasang; Socorro Lupisan; Jean Lang; Remi Forrat; Anh Wartel; Denis Crevat
Journal:  Vaccine       Date:  2011-04-06       Impact factor: 3.641
View more
  51 in total

1.  A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Kari Opert; Adrienne P Jarvis; Beulah P Sabundayo; Benjamin D McElvany; Eli A Sendra; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2016-02-16       Impact factor: 5.226

Review 2.  Prospects for dengue vaccines for travelers.

Authors:  Sl-Ki Lim; Yong Seok Lee; Suk Namkung; Jacqueline K Lim; In-Kyu Yoon
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

3.  Potential Point-of-Care Testing for Dengue Virus in the Field.

Authors:  Wei-Kung Wang; Duane J Gubler
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

Review 4.  Point of care testing for infectious diseases.

Authors:  Hui Chen; Kengku Liu; Zhao Li; Ping Wang
Journal:  Clin Chim Acta       Date:  2019-03-08       Impact factor: 3.786

Review 5.  Potential for treatment and a Zika virus vaccine.

Authors:  Natalie Quanquin; Lulan Wang; Genhong Cheng
Journal:  Curr Opin Pediatr       Date:  2017-02       Impact factor: 2.856

6.  Prodrug Activation by a Viral Protease: Evaluating Combretastatin Peptide Hybrids To Selectively Target Infected Cells.

Authors:  Michael Richter; Mila M Leuthold; Dominik Graf; Ralf Bartenschlager; Christian D Klein
Journal:  ACS Med Chem Lett       Date:  2019-07-18       Impact factor: 4.345

7.  Fighting the Dengue Virus.

Authors:  Aniqa Faraz; Muhammad Aadil; Muhammad Nabeel Shafqat
Journal:  Cureus       Date:  2017-05-24

8.  Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.

Authors:  Jian Hang Lam; Yen Leong Chua; Pei Xuan Lee; Julia María Martínez Gómez; Eng Eong Ooi; Sylvie Alonso
Journal:  JCI Insight       Date:  2017-12-21

9.  Computational predictions suggest that structural similarity in viral polymerases may lead to comparable allosteric binding sites.

Authors:  Jodian A Brown; Marie V Espiritu; Joel Abraham; Ian F Thorpe
Journal:  Virus Res       Date:  2016-06-01       Impact factor: 3.303

Review 10.  Immune correlates for dengue vaccine development.

Authors:  Anon Srikiatkhachorn; In-Kyu Yoon
Journal:  Expert Rev Vaccines       Date:  2015-11-24       Impact factor: 5.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.